Cosmos Health INC

Cosmos Health Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors and the approval of Series B Preferred Stock.

Cosmos Health Inc. announced its Board of Directors has authorized a share repurchase program of up to $5 million of its common stock, reflecting confidence in the company's fundamentals and growth prospects.

Cosmos Health reported record first-quarter revenue of $17.9 million, a 31% year-over-year increase, alongside a significant reduction in total liabilities.

Cosmos Health achieved record annual revenue of $65.3 million in 2025, representing a 20% year-over-year increase.

Cosmos Health Inc. received a non-compliance letter from Nasdaq for failing to maintain its minimum bid price, facing potential delisting.

Cosmos Health Inc. reported record third-quarter 2025 financial results, driven by significant revenue and gross profit growth across all core business segments and a strengthened cash position.

Cosmos Health Inc. reported a significant increase in revenue for Q3 and the nine months ended September 30, 2025, driven by strategic expansions and acquisitions, though net losses widened due to substantial non-cash charges and increased financing costs.

Cosmos Health Inc. reported increased revenue and gross profit for Q2 2025, alongside a reduced net loss, but acknowledged persistent substantial doubt about its ability to continue as a going concern despite securing a new $300 million convertible note facility.

Cosmos Health Inc.'s Q1 2025 results show a slight revenue decrease but a significant reduction in net loss, driven by a shift towards higher-margin product lines and cost management efforts.

Cosmos Health Inc. reported its third quarter 2024 results, showing a slight decrease in revenue compared to the same period last year, while also expressing substantial doubt about its ability to continue as a going concern.

Cosmos Health Inc. reports a 12.45% increase in revenue year-over-year for the six months ended June 30, 2024, while also noting a net loss of $4.45 million.

Cosmos Health Inc. saw a revenue increase in the first quarter of 2024, but also experienced a larger net loss compared to the same period last year.

Cosmos Health reports 2025 revenue growth to $65.3 million while highlighting ongoing going concern risks and material weaknesses in internal controls.

Cosmos Health Inc. reports a net loss of $16.18 million on revenue of $54.43 million for fiscal year 2024, while addressing concerns about its ability to continue as a going concern.

Cosmos Health Inc. reported a net loss of $18.5 million on revenue of $53.4 million for 2023, marking a year of strategic acquisitions and operational expansion alongside financial challenges.

Grigorios Siokas, Chief Executive Officer, a Director and 10% owner of Cosmos Health Inc., purchased 349,825 shares of common stock on 2026-07-30-05:00 for $0.20 per share.

Georgios Terzis, Chief Financial Officer of Cosmos Health Inc., received 328,407 shares of common stock on 2026-07-29-05:00.

Grigorios Siokas, Chief Executive Officer, a Director and 10% owner of Cosmos Health Inc., purchased 766,284 shares of common stock on 2026-07-29-05:00 for $0.18 per share.

Cosmos Health Inc. reports that Chief Financial Officer Georgios Terzis acquired 168,135 shares of common stock through a debt exchange, valued at $0.2498 per share.

CEO Grigorios Siokas acquired 218,447 shares of Cosmos Health Inc. through a debt-for-equity exchange valued at $45,000.

CEO Grigorios Siokas acquired 701,447 shares of Cosmos Health Inc. through a $160,000 debt-for-equity exchange.

Cosmos Health Inc. has issued a proxy statement detailing the agenda for its 2026 Annual Meeting of Stockholders, including director elections, auditor ratification, equity plan approval, and preferred stock issuance.

Cosmos Health Inc. details its strategic vision, financial performance, and future growth initiatives, including a $300 million digital asset facility and U.S. manufacturing expansion.

Cosmos Health Inc. calls its 2025 Annual Meeting to vote on critical proposals including a discretionary reverse stock split, a $300 million convertible note issuance, and a new 2025 equity incentive plan.

Cosmos Health Inc. issues a supplement to its proxy statement to correct the number of common shares held by Grigorios Siokas.

Cosmos Health Inc. is convening its 2024 Annual Meeting of Stockholders to vote on key proposals including director elections, warrant issuance, auditor ratification, an equity incentive plan, and authorization for reverse stock splits.

Cosmos Health Inc. is seeking to raise up to $7.5 million through a new offering of common stock and warrants to address its significant operating losses and substantial doubt about its ability to continue as a going concern, while also facing a Nasdaq minimum bid price non-compliance notice.

Cosmos Health Inc. files an amendment to its Form S-1 registration statement, updating exhibits related to legal and accounting consents.

Cosmos Health Inc. amends its S-1 filing, outlining a proposed $7.5 million offering and providing updates on its financial condition and recent transactions.

Cosmos Health Inc. is offering up to 10,714,286 shares of common stock, pre-funded warrants, and common warrants in a best-efforts offering.

Cosmos Health Inc. is offering up to 10,714,286 shares of common stock, pre-funded warrants, and common warrants in a best-efforts offering to raise capital.

Cosmos Health Inc. is offering up to $12 million in common stock, pre-funded warrants, and common warrants in a best-efforts offering.

Cosmos Health Inc. CEO Grigorios Siokas has increased his beneficial ownership in the company to 22.9% through a series of debt-to-equity exchange agreements, converting approximately $745,000 of company debt into common stock.

Cosmos Health Inc. CEO Grigorios Siokas has increased his beneficial ownership in the company to 16.6% through a series of debt-for-equity exchange agreements, as detailed in a recent Schedule 13D amendment.

Cosmos Health Inc.'s CEO, Grigorios Siokas, has increased his beneficial ownership to 17% of the common stock through a series of debt-to-equity exchange agreements, converting $455,000 of company debt into shares.

Individual investor Andreas Bovopoulos has filed a Schedule 13G reporting a 7.2% beneficial ownership stake in Cosmos Health Inc.

Individual investor Andreas Bovopoulos has filed a Schedule 13G reporting an 8.15% beneficial ownership stake in Cosmos Health Inc.

Andreas Bovopoulos has filed an amended Schedule 13G, disclosing a 4.8% beneficial ownership stake in Cosmos Health Inc. common stock.

Armistice Capital and Steven Boyd report a 4.99% beneficial ownership stake in Cosmos Health Inc. common stock as of June 30, 2025.

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, disclosing a shared beneficial ownership of 7.03% of Cosmos Health Inc.'s common stock.

Andreas Bovopoulos has filed a Schedule 13G, reporting beneficial ownership of 6.97% of Cosmos Health Inc.'s common stock as of December 31, 2024.